Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Czachorowski, Maciej Jca
- dc.contributor.author Amaral, André F.S.ca
- dc.contributor.author Montes-Moreno, Santiagoca
- dc.contributor.author Lloreta, Josep, 1958-ca
- dc.contributor.author Carrato, Alfredoca
- dc.contributor.author Tardón, Adoninaca
- dc.contributor.author Morente, Manuel Mca
- dc.contributor.author Kogevinas, Manolisca
- dc.contributor.author Real, Francisco X.ca
- dc.contributor.author Malats i Riera, Núriaca
- dc.date.accessioned 2015-05-12T09:47:07Z
- dc.date.available 2015-05-12T09:47:07Z
- dc.date.issued 2012ca
- dc.description.abstract Aberrant overexpression of cyclooxygenase-2 (COX2) is observed in urothelial carcinoma of the bladder (UCB). Studies evaluating COX2 as a prognostic marker in UCB report contradictory results. We determined the prognostic potential of COX2 expression in UCB and quantitatively summarize the results with those of the literature through a meta-analysis. Newly diagnosed UCB patients recruited between 1998–2001 in 18 Spanish hospitals were prospectively included in the study and followed-up (median, 70.7 months). Diagnostic slides were reviewed and uniformly classified by expert pathologists. Clinical data was retrieved from hospital charts. Tissue microarrays containing non-muscle invasive (n = 557) and muscle invasive (n = 216) tumours were analyzed by immunohistochemistry using quantitative image analysis. Expression was evaluated in Cox regression models to assess the risk of recurrence, progression and disease-specific mortality. Meta-hazard ratios were estimated using our results and those from 11 additional evaluable studies. COX2 expression was observed in 38% (211/557) of non-muscle invasive and 63% (137/216) of muscle invasive tumors. Expression was associated with advanced pathological stage and grade (p<0.0001). In the univariable analyses, COX2 expression - as a categorical variable - was not associated with any of the outcomes analyzed. As a continuous variable, a weak association with recurrence in non-muscle invasive tumors was observed (p-value = 0.048). In the multivariable analyses, COX2 expression did not independently predict any of the considered outcomes. The meta-analysis confirmed these results. We did not find evidence that COX2 expression is an independent prognostic marker of recurrence, progression or survival in patients with UCB.en
- dc.description.sponsorship The work was partially supported by the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Ministry of Science and Innovation, Spain (G03/174, 00/0745, PI051436, PI061614 and G03/174); Red Temática de Investigación Cooperativa en Cáncer- RD06/0020-RTICC; Consolider ONCOBIO; EU-FP6-STREP-37739-DRoP-ToP; EU-FP7-HEALTH-F2-2008-201663-UROMOL; EU-FP7-HEALTH-F2-2008-201333-DECanBio; USA-NIH-RO1-CA089715; and a PhD fellowship awarded to MJC from the ‘‘la Caixa’’ foundation, Spain, and a postdoctoral fellowship awarded to AFSA from the Fundación Científica de la AECCen
- dc.format.mimetype application/pdfca
- dc.identifier.citation Czachorowski MJ, Amaral AFS, Montes-Moreno S, Lloreta J, Carrato A, Tardón A et al. Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. PLoS ONE. 2012;7(9):e45025. DOI: 10.1371/journal.pone.0045025ca
- dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0045025
- dc.identifier.issn 1932-6203ca
- dc.identifier.uri http://hdl.handle.net/10230/23558
- dc.language.iso engca
- dc.publisher Public Library of Science (PLoS)ca
- dc.relation.ispartof PLoS ONE. 2012;7(9):e45025
- dc.relation.projectID info:eu-repo/grantAgreement/EC/FP6/37739ca
- dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/201663
- dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/201333
- dc.rights © 2012 Czachorowski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are crediteden
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.other Bufeta -- Càncer -- Etiologia -- Diferències entre sexesca
- dc.title Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysisen
- dc.type info:eu-repo/semantics/articleca
- dc.type.version info:eu-repo/semantics/publishedVersionca